

# Changes in Features of the Metabolic Syndrome and Incident Impaired Glucose Regulation or Type 2 Diabetes in a Chinese Population

JIAN-JUN WANG, MD<sup>1</sup>  
GANG HU, MD, PHD<sup>1,2</sup>  
JANI LAPPALAINEN, BSC<sup>1</sup>

MAIJA E. MIETTINEN, MSC<sup>1</sup>  
QING QIAO, MD, PHD<sup>1,2</sup>  
JAAKKO TUOMILEHTO, MD, PHD<sup>1,2</sup>

The current understanding of the pathogenesis of type 2 diabetes is mainly based on a large number of cross-sectional and prospective studies (1–4) in which nondiabetic individuals were followed for several years to determine incident cases of diabetes without repeating assessment of other metabolic characteristics except for assay of plasma glucose during follow-up. In fact, only the studies in the Pima Indian population (5–7) have examined the changes in anthropometric characteristics, insulin secretion, and insulin action during the progression from normal glucose tolerance (NGT) to impaired glucose tolerance (IGT) to diabetes. Thus far, no study has directly addressed the effects of changes in the components of the metabolic syndrome on the transition to diabetes in other populations. The purpose of this study was to investigate the changes in the features of the metabolic syndrome during the transition from one state of glucose homeostasis to another in a cohort of Chinese people and to understand the relative contributions of these changes to the development of im-

paired glucose regulation (IGR) or type 2 diabetes.

## RESEARCH DESIGN AND METHODS

A total of 627 subjects without diabetes at baseline who participated in the National Diabetes Survey in 1994 and the follow-up survey in 1999 in the Beijing area (8) were included in this study. All of the subjects had measurements of BMI, blood pressure, fasting serum total cholesterol, triglycerides, insulin, plasma fasting glucose, and 2-h postload glucose (2-hPG) at baseline and follow-up separately. Past medical history, family history of diabetes, history of pharmacological treatment, smoking status, education, and occupation were determined with a standardized questionnaire. Obesity was defined as BMI  $\geq 25.0$  kg/m<sup>2</sup>, according to the recommendations for Asians (9). Hypertension was defined as systolic blood pressure  $\geq 140$  mmHg and/or diastolic blood pressure  $\geq 90$  mmHg or using antihypertensive drugs (10). Insulin resistance was defined as upper fasting insulin quartile at baseline or upper fasting insulin quartile at baseline as a cut-

off during the follow-up (11). Dyslipidemia was defined as serum triglycerides  $\geq 1.7$  mmol/l or taking hypolipidemic medication.

According to the World Health Organization 1999 criteria for glucose intolerance (10), the participants were classified into the following categories of glycemic status based on fasting plasma glucose (FPG) and 2-hPG: normal fasting glucose (NFG) and NGT (FPG  $< 6.1$  mmol/l and 2-hPG  $< 7.8$  mmol/l); IGR, including impaired fasting glucose (IFG) and/or IGT (FPG between 6.1 and 7.0 mmol/l and/or 2-hPG between 7.8 and 11.1 mmol/l); and diabetes (FPG  $\geq 7.0$  mmol/l and/or 2-hPG  $\geq 11.1$  mmol/l).

## Statistical analyses

All statistical analyses were done with SPSS 11.0 software. Paired *t* tests and McNemar tests were performed to compare changes within groups. Between-group comparisons in mean changes or percentage changes among six groups were tested by repeated-measures ANOVA (time  $\times$  group effect) for continuous variables or by the Mantel-Haenszel method for categorical variables adjusted for age and sex separately. A multiple logistic regression was applied with the change in obesity, hypertension, dyslipidemia, and insulin resistance as independent variables and glucose status at baseline and follow-up as the dependent variable. Subjects who remained NGT and those who had IGR at baseline and reverted to NGT during follow-up were created as a reference group, and subjects who retained IGR and who had NGT or IGR at baseline and progressed to IGR or diabetes during follow-up were defined as incident IGR or diabetes. The analyses multivariate models were carried out adjusting for age, sex, family history of diabetes, smoking, education, occupation, antihypertensive and hypolipidemic medication, FPG, 2-hPG, systolic blood pressure, BMI, total chole-

From the <sup>1</sup>Diabetes and Genetic Epidemiology Unit, Department of Epidemiology and Health Promotion, National Public Health Institute, Helsinki, Finland; and the <sup>2</sup>Department of Public Health, University of Helsinki, Helsinki, Finland.

Address correspondence and reprint requests to Dr. Jian-jun Wang, Diabetes and Genetic Epidemiology Unit, Department of Epidemiology and Health Promotion, National Public Health Institute, KTL/GE-Lab, Kyto-suontie 11, FIN-00300 Helsinki, Finland. E-mail: jianjun.wang@ktl.fi.

Received for publication 20 October 2004 and accepted 21 October 2004.

**Abbreviations:** 2-hPG, 2-h postload glucose; FPG, fasting plasma glucose; IGR, impaired glucose regulation; IGT, impaired glucose tolerance; NFG, normal fasting glucose; NGT, normal glucose tolerance.

A table elsewhere in this issue shows conventional and Système International (SI) units and conversion factors for many substances.

© 2005 by the American Diabetes Association.

The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. Section 1734 solely to indicate this fact.

Table 1—Within- and between-group comparisons of changes in characteristics between baseline and follow-up among six groups

	Baseline NGT			Baseline IGR			Time × group effect*
	Follow-up			Follow-up			
	NGT	IGR	Diabetes	NGT	IGR	Diabetes	
n	213	94	51	90	84	95	
Age at baseline (years)†	47 ± 11	48 ± 10	49 ± 11	47 ± 11	51 ± 10	50 ± 10	0.013
BMI at baseline (kg/m <sup>2</sup> )†	23.7 ± 3.2	24.9 ± 3.2	25.2 ± 3.7	24.6 ± 3.3	24.9 ± 3.0	26.2 ± 3.5	0.001
BMI at follow-up (kg/m <sup>2</sup> )†	24.6 ± 3.4	26.2 ± 5.2	26.1 ± 3.5	25.0 ± 3.5	26.1 ± 3.1	26.6 ± 3.2	0.002
Change in BMI (kg/m <sup>2</sup> )	<b>0.9 ± 2.1</b> (3.8)	<b>1.3 ± 4.7</b> (5.2)	<b>0.9 ± 2.1</b> (3.6)	<b>0.4 ± 2.0</b> (1.6)	<b>1.2 ± 3.0</b> (4.8)	0.4 ± 2.3 (1.5)	NS
Change in obesity‡	5 (16)	<b>20 (44)</b>	14 (30)	0 (0)	<b>19 (40)</b>	6 (9.4)	0.002
Change in hypertension	<b>8 (31)</b>	<b>16 (40)</b>	<b>12 (22)</b>	<b>10 (21)</b>	<b>16 (39)</b>	<b>17 (33)</b>	NS
Change in dyslipidemia	0 (0)	3 (11)	0 (0)	-10 (-27)	3 (7.3)	4 (7)	NS
Change in insulin resistance	<b>6 (35)</b>	<b>19 (73)</b>	<b>16 (64)</b>	7 (29)	<b>13 (54)</b>	<b>14 (34)</b>	NS

Data are means ± SD or percentage (percentage change). Percentage change (given in parentheses) in a variable is expressed as a percentage at the baseline examination.  $P < 0.05$  within-group comparisons between baseline and follow-up are in bold. \*Between-group comparisons adjusted for age and sex among all six groups. †ANOVA adjusted for sex (age at baseline) and age. ‡Adjusted OR for incident IGR or diabetes was 2.20 (95% CI 1.36–3.57).

terol, triglycerides, and fasting insulin at baseline.

**RESULTS**— Table 1 shows within- and between-group comparisons of changes in characteristics between baseline and follow-up among six groups. The highest increased trend of these risk factors, especially for the mean values of BMI and prevalence of obesity, hypertension, and insulin resistance, occurred during the transition from NGT to IGR and was followed by the retaining IGR and the transition from NGT to diabetes during follow-up. The smallest increased trend in prevalence of obesity, hypertension, and insulin resistance was seen in the subjects who reverted from IGR to NGT; however, the difference of change between groups was significant only for obesity. Change in obesity was positively and significantly associated with the risk of incident IGR or diabetes with an odds ratio (OR) of 2.20 (95% CI 1.36–3.57) after adjustment for age, sex, family history of diabetes, smoking, education, occupation, antihypertensive and hypolipidemic medication, FPG, 2-hPG, systolic blood pressure, BMI, total cholesterol, triglycerides, fasting insulin at baseline, and change in hypertension, dyslipidemia, and insulin resistance.

**CONCLUSIONS**— In this study, the subjects who remained normal glucose tolerant and those who progressed from NGT to diabetes during follow-up had an almost similar increase in mean BMI. Nevertheless, the former still kept the mean BMI <25 kg/m<sup>2</sup> (24.6 kg/m<sup>2</sup>) dur-

ing the follow-up, while the progressors had a mean BMI of 26.1 kg/m<sup>2</sup>. Interestingly, BMI also increased in the subjects who reverted from IGR to NGT during follow-up, but their mean BMI remained ~25 kg/m<sup>2</sup>, and no change in the prevalence of obesity was observed. Furthermore, an increase in obesity rather than change in other features of the metabolic syndrome predicted the progression of IGR or diabetes, after adjustment of the confounding factors. These results implicate that obesity may be a more important risk factor for the development of IGR or diabetes than other features of the metabolic syndrome. The lifestyle intervention aiming at preventing diabetes should place higher importance on obesity than IGR, because IGR can still revert to a normal glucose state if an increase in obesity does not occur or mean BMI is being kept <25 kg/m<sup>2</sup>.

**Acknowledgments**— This work was supported by a grant from the Bureau of Public Health of Beijing, the Preventive and Treatment Office of Beijing, and the Academy of Finland (46558, 77618, 204274, and 205657).

#### References

- Haffner SM, Stern MP, Mitchell BD, Hazuda HP, Patterson JK: Incidence of type II diabetes in Mexican Americans predicted by fasting insulin and glucose levels, obesity, and body-fat distribution. *Diabetes* 39:283–288, 1990
- Liese AD, Mayer-Davis EJ, Tyroler HA, Davis CE, Keil U, Duncan BB, Heiss G: Development of the multiple metabolic

syndrome in the ARIC cohort: joint contribution of insulin, BMI, and WHR. Atherosclerosis Risk in Communities. *Ann Epidemiol* 7:407–416, 1997

- Klein BE, Klein R, Lee KE: Components of the metabolic syndrome and risk of cardiovascular disease and diabetes in Beaver Dam. *Diabetes Care* 25:1790–1794, 2002
- Carnethon MR, Palaniappan LP, Burchfiel CM, Brancati FL, Fortmann SP: Serum insulin, obesity, and the incidence of type 2 diabetes in black and white adults: the Atherosclerosis Risk in Communities study: 1987–1998. *Diabetes Care* 25:1358–1364, 2002
- Hanson RL, Narayan KM, McCance DR, Pettitt DJ, Jacobsson LT, Bennett PH, Knowler WC: Rate of weight gain, weight fluctuation, and incidence of NIDDM. *Diabetes* 44:261–266, 1995
- Saad MF, Knowler WC, Pettitt DJ, Nelson RG, Mott DM, Bennett PH: Sequential changes in serum insulin concentration during development of non-insulin-dependent diabetes. *Lancet* 1:1356–1359, 1989
- Weyer C, Bogardus C, Mott DM, Pratley RE: The natural history of insulin secretory dysfunction and insulin resistance in the pathogenesis of type 2 diabetes mellitus. *J Clin Invest* 104:787–794, 1999
- Wang JJ, Qiao Q, Miettinen ME, Lappalainen J, Hu G, Tuomilehto J: The metabolic syndrome defined by factor analysis and incident type 2 diabetes in a Chinese population with high postprandial glucose. *Diabetes Care* 27:2429–2437, 2004
- Steering Committee of the Western Pacific Region of the World Health Organization, the International Association for the Study of Obesity, the International Obesity Task Force: The Asia-Pacific perspective: redefining obesity and its treatment. Melbourne, Australia, Health

- Communications Australia Pty Limited, 2000. Available at [http://www.diabetes.com.au/downloads/obesity\\_report.pdf](http://www.diabetes.com.au/downloads/obesity_report.pdf)
10. World Health Organization: *Definition, Diagnosis and Classification of Diabetes Mellitus and its Complications: Report of a WHO Consultation. Part 1: Diagnosis and Classification of Diabetes Mellitus*. Geneva, World Health Org., 1999 (publ. no. WHO/NCD/NCS/99.2)
  11. Balkau B, Charles MA: Comment on the provisional report from the WHO consultation: European Group for the Study of Insulin Resistance (EGIR). *Diabet Med* 16: 442–443, 1999